TABLE 3.
STUDY | TYPE OF EVIDENCE | COMMENTS |
---|---|---|
Molindone (Fernandez F, Levy JK) n=4 | Case study | Molindone safe and effective |
Loxapine versus olanzapine (Kreiger D, et al.) n=1 | Case study | Loxapine superior to olanzapine |
Loxapine versus thioridazine (Versiani M, et al.) n=40 (20 patients per group) | RCT | Loxapine superior to thioridazine in one trial of a two-part study but equivalent in other part |
Thiothixine verus haloperidol (Peterson LG, Bognar B) n=14 (8 and 6 patients respectively) | RCT | Haloperidol superior to thiothixene |
Haloperidol, chlorpromazine, and lorazepam (Breitbart W, et al.) n=30 (11, 13, and 6 patients in each respective group) | RCT | Only study selected by Cochrane Collaboration. Both haloperidol and chlorpromazine superior to lorazepam |
Haloperidol, olanzapine, and placebo (Hu X, Deng W, Yang H) n=175 (72, 74, and 29 patients in each respective group) | RCT | Haloperidol equivalent to olanzapine and both superior to placebo |
KEY:
- RCT—
randomized, controlled trial